- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Graft versus host disease
- Meeting Date: September 2022
- Public Summary Document (PSD) September 2022 PBAC Meeting - (PDF 1.8MB)
- Public Summary Document (PSD) September 2022 PBAC Meeting - (Word 665KB)
Ruxolitinib – September 2022
Ruxolitinib: Tablet 5 mg, Tablet 10 mg; Jakavi® – September 2022
Last updated
30 May 2025